understanding the different cryptocurrencies searches

Industrial Securities' investment strategy for the construction industry in 2025: internal and external resonance, optimistic about debt conversion and the "Belt and Road" industry, Industrial Securities Research Report said that the construction industry will face certain pressure in 2024, and it is expected that infrastructure investment will remain high in 2025, driven by the debt conversion policy. Review and prospect of plate market: central state-owned enterprises and design plates led the gains, with obvious excess returns. Main line 1: Debt conversion is expected to drive the improvement of the management quality of construction central enterprises. 1) The driving force and mode of action of this debt conversion can be compared with the "Belt and Road" market in 2014 and the PPP market in 2016, and the policy is driven from top to bottom. 2) The institutions' positions in construction central enterprises are low, and the valuation of construction central enterprises is also in the lower position of the historical center. 3) The unprecedented intensity of debt conversion will help the central enterprises to realize the double promotion of EPS and PE. Main Line 2: The Belt and Road Initiative is expected to accelerate and benefit international engineering enterprises. The "Belt and Road" market has accelerated its expansion, and international engineering enterprises are expected to accelerate their going out to sea, and their performance and valuation have both improved.According to Siemens, digital business revenue has more than doubled this year, reaching 1.7 billion euros, exceeding the commitment in 2021 ahead of schedule.There are more than 100 suppliers who need to pay for the goods. On December 12, after learning that the capital chain of Jiyue Automobile was broken, many suppliers from all over the country came to Jiyue Automobile Headquarters Building and asked Jiyue Automobile to pay for the goods. The reporter learned that there are more than 100 employees in the supplier group established at the site. These suppliers undertake many businesses, including equipment, fine products, insurance, electronics, batteries, etc., and the maximum payment required by the company is up to 100 million yuan. Most suppliers owe between 1 million yuan and 10 million yuan. Among them, the total amount of arrears registered by 19 suppliers in the group is nearly 96 million yuan, and the average balance of arrears of each supplier exceeds 5 million yuan. (CBN)

CITIC Securities: There is no need to be overly pessimistic about the export of home appliances catalyzed by state subsidies. CITIC Securities Research Report said that domestically, the sales data of white electricity and black electricity continued to improve under the support of state subsidies. Externally, the overall export exposure of home appliance enterprises to the United States is relatively limited, so there is no need to be overly pessimistic. Looking forward to the future, the domestic demand stimulus policy is expected to be further overweight, and it is suggested to focus on white power enterprises that benefit from state subsidies; Optional sectors where domestic demand is expected to reverse (small household appliances, projection).Nanxin Technology: The equity of shareholders Shunwei Technology and its concerted actions changed to less than 5%. Nanxin Technology announced that the shareholders of the company Shunwei Technology and its concerted actions Hangzhou Shunying, Wuhan Shunying and Wuhan Shunhong reduced their holdings of the company's shares and passively diluted their equity, and the total number of shares held by the company changed from 30,843,800 shares to 21,272,800 shares, accounting for 7.2826% to 4.9999% of the company's total share capital, no longer.Spot platinum just broke through the $940.00/oz mark, and the latest price was $939.71/oz, up 0.45% in the day; The main force of Nymex platinum futures recently reported $955.7 per ounce, up 0.52% in the day.

Yuncong Technology: "The R&D team of large-scale model agent products is basically dissolved" is all false information. Yuncong Technology said on the interactive platform that the company's R&D team is stable at present, and a rigorous and meticulous hierarchical division of labor system has been established for the research and development of large-scale model related products. The configuration of R&D echelon will be flexibly adjusted according to the continuous evolution of large model technology and the changes of market demand of agent products. The statements of "the No.1 position of the big model algorithm" and "the R&D team of the big model agent product is basically dissolved" mentioned in the question are false information, and the company reserves the right to pursue legal responsibility for this. The company has been unswervingly promoting the research and product development of large-scale model and agent-related technologies.Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.